Treace to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Treace Medical Concepts (Nasdaq: TMCI) announced that CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at ~7:30 am PT. A live webcast and replay of the fireside chat will be available on the company’s investor relations website at https://investors.treace.com/. The company also noted it routinely posts investor‑important information in its Investor Relations section and encourages investors to check the site regularly for updates.
Positive
- None.
Negative
- None.
News Market Reaction – TMCI
On the day this news was published, TMCI declined 1.21%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves (e.g., KIDS +1.79%, BVS +1.21%, CTKB -0.39%). One peer, CBLL, also announced J.P. Morgan Healthcare Conference participation, but momentum data show no coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Debt financing update | Neutral | -3.5% | New five-year senior secured loan facilities totaling up to $175M. |
| Nov 07 | Investor conferences | Neutral | -28.3% | Announcement of participation in two November healthcare investor conferences. |
| Nov 06 | Q3 2025 earnings | Negative | -0.3% | Q3 results with guidance cut and continued net losses despite revenue growth. |
| Oct 23 | Earnings date notice | Neutral | +1.2% | Notice of timing and access details for upcoming Q3 2025 results call. |
| Sep 10 | Clinical data update | Positive | -5.4% | Positive AOFAS clinical data and new bunion treatment technologies unveiled. |
Recent news, including earnings, financing, and positive clinical data, has often been followed by flat to negative moves, even on objectively positive or neutral updates.
Over the last six months, TMCI reported Q3 2025 results on Nov 6 with revenue of $50.2M, a net loss of $16.3M, and reduced full‑year revenue guidance, which saw only a small share price decline. Subsequent announcements included conference participations on Nov 10–11, new debt facilities of up to $175M on Dec 18, and earlier positive clinical data with low recurrence rates. This J.P. Morgan conference appearance fits the pattern of ongoing investor outreach following financing and operational updates.
Market Pulse Summary
This announcement highlights TMCI’s plan to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, continuing its investor outreach after Q3 2025 earnings and a new debt financing package. The company remains near its 52‑week low and trades below its $5.97 200‑day moving average, so investors may focus on any incremental commentary on growth, profitability, and balance sheet flexibility shared during the fireside chat.
AI-generated analysis. Not financial advice.
PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately 7:30 am PT.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System and the SpeedMTP® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide™ patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
FAQ
When will Treace (TMCI) present at the J.P. Morgan Healthcare Conference?
How can investors watch Treace (TMCI) presentation at the J.P. Morgan conference?
What topics will Treace (TMCI) likely cover in the January 14, 2026 fireside chat?
Where does Treace post investor information and updates ahead of the TMCI presentation?
Will a replay of the Treace (TMCI) J.P. Morgan presentation be available after the event?
